Cytokinetics
CYTK
190 hedge funds and large institutions have $1.45B invested in Cytokinetics in 2021 Q2 according to their latest regulatory filings, with 20 funds opening new positions, 69 increasing their positions, 66 reducing their positions, and 22 closing their positions.
79% more call options, than puts
Call options by funds: $10M | Put options by funds: $5.6M
5% more repeat investments, than reductions
Existing positions increased: 69 | Existing positions reduced: 66
0.12% more ownership
Funds ownership: 105.26% → 105.38% (+0.12%)
0% more funds holding in top 10
Funds holding in top 10: 5 → 5 (0)
9% less first-time investments, than exits
New positions opened: 20 | Existing positions closed: 22
1% less funds holding
Funds holding: 192 → 190 (-2)
17% less capital invested
Capital invested by funds: $1.74B → $1.45B (-$291M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$109M |
| 2 |
CC
Commodore Capital
New York
|
+$16.5M |
| 3 |
LGM
Logos Global Management
San Francisco,
California
|
+$16.4M |
| 4 |
AG
Artal Group
Luxembourg
|
+$11.7M |
| 5 |
FCM
Farallon Capital Management
San Francisco,
California
|
+$8.83M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
MWNA
Marshall Wace North America
New York
|
-$36.5M |
| 2 |
DM
Deerfield Management
New York
|
-$31.1M |
| 3 |
RM
RP Management
New York
|
-$20.4M |
| 4 |
Adage Capital Partners
Boston,
Massachusetts
|
-$19.7M |
| 5 |
CCM
CAAS Capital Management
New York
|
-$15.6M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
BAM
201
Blueshift Asset Management
Red Bank,
New Jersey
| – | -$211K | -9,089 | Closed |
|
|
HA
202
HC Advisors
Sandy Springs,
Georgia
| – | -$210K | -9,009 | Closed |
|
203
Pacer Advisors
Malvern,
Pennsylvania
| – | -$79K | -3,417 | Closed |
|
|
QT
204
Quantbot Technologies
New York
| – | -$44K | -1,900 | Closed |
|
|
VCM
205
Versant Capital Management
Phoenix,
Arizona
| – | -$10K | -419 | Closed |
|
|
WAP
206
Wealthcare Advisory Partners
West Chester,
Pennsylvania
| – | -$10K | -410 | Closed |
|
|
ADIM
207
Alpha DNA Investment Management
Columbia,
Maryland
| – | -$1K | -71 | Closed |
|
|
CTC
208
Central Trust Company
Jefferson City,
Missouri
| – | -$2K | -70 | Closed |
|
|
IA
209
IFP Advisors
Tampa,
Florida
| – | -$916 | -39 | -72% |
|
|
FHA
210
First Horizon Advisors
Memphis,
Tennessee
| – | +$493 | +21 | +78% |
|
CYTK Hedge Fund Activity: Q2 2021 in Review
190 of the 5,745 institutional investors tracked by Wall St. Rank reported a position in Cytokinetics (CYTK) for Q2 2021, worth a combined $1.45B — down 17% from $1.74B a quarter earlier.
Sellers outnumbered buyers: 22 funds closed out of CYTK and 20 opened new positions — a net loss of 2 holders — while 66 trimmed existing stakes and 69 added.
The largest buyer was Fidelity Investments, adding an estimated $109M. The largest seller was Marshall Wace North America, cutting an estimated $36.5M.
- 190 institutional investors held Cytokinetics (CYTK) as of Q2 2021, down from 192 in Q1 2021.
- Funds reported $1.45B of Cytokinetics stock for Q2 2021, down 17% quarter-over-quarter.
- 20 funds opened new Cytokinetics positions in Q2 2021 and 22 closed out, a net change of -2 holders.
- The largest Cytokinetics buyer in Q2 2021 was Fidelity Investments, an estimated $109M added.
- The largest Cytokinetics seller in Q2 2021 was Marshall Wace North America, an estimated $36.5M sold.
Based on aggregated 13F filings for Q2 2021.